KEFLEX (cephalexin) by Pragma Bio is [see microbiology ( )] . First approved in 1971.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
KEFLEX (cephalexin) is an oral first-generation cephalosporin antibiotic approved in 1971 for treating bacterial infections. It inhibits bacterial cell wall synthesis by binding penicillin-binding proteins. The suspension formulation enables pediatric and patients unable to swallow capsules.
As LOE approaches, the brand team is likely focused on lifecycle management and volume maintenance rather than growth initiatives, with smaller commercial footprint.
[see Microbiology ( )] .
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Oral Amoxicillin and Cephalexin PK/PD in Neonates
Cefadroxil and Cephalexin Drug Levels and Dosing in Pediatric Musculoskeletal Infections
A Study of Cephalexin Liquid in Healthy Participants
A Study of Cephalexin Liquid for Pediatrics in Healthy Adults Participants
A Study of Cephalexin Suspension in Healthy Participants
Worked on KEFLEX at Pragma Bio? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on KEFLEX offers limited growth trajectory but provides foundational commercial and regulatory experience in a stable, mature antibiotic franchise. Career advancement depends on driving operational efficiency, defending market share against generics, and managing lifecycle transition.